Prelude Therapeutics (PRLD) Depreciation & Amortization (CF) (2019 - 2026)

Prelude Therapeutics has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $391000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 10.11% year-over-year to $391000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 6.4% YoY) and the FY2025 annual result came in at $1.7 million, down 3.44% from the prior year.
• Depreciation & Amortization (CF) slipped to $391000.0 in Q1 2026 per PRLD's latest filing, from $418000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $489000.0 in Q4 2024 and troughed at $278000.0 in Q1 2023.
• A 5-year average of $374529.4 and a median of $391000.0 in 2026 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) surged 91.88% in 2022, then slipped 17.21% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $362000.0 in 2022, then decreased by 8.56% to $331000.0 in 2023, then surged by 47.73% to $489000.0 in 2024, then declined by 14.52% to $418000.0 in 2025, then retreated by 6.46% to $391000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $391000.0, $418000.0, and $425000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.